Brief: Biocryst Receives Early Termination Of Hart-Scott-Rodino Waiting Period For Astria Acquisition
03/12/2025 13:05
Dec 3 (Reuters) - BioCryst Pharmaceuticals Inc BCRX.O: BIOCRYST RECEIVES EARLY TERMINATION OF HART-SCOTT-RODINO WAITING PERIOD FOR ASTRIA ACQUISITION BIOCRYST PHARMACEUTICALS INC - EXPECTS MERGER TO CLOSE IN Q1 2026 Source text: ID:nGNX6KMFNc Further company coverage: BCRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026